Spinal Cord Injuries
Conditions
Brief summary
This study will employ a randomized, wait-list controlled trial. A total of 30 participants (15 experimental, 15 wait-list control) between 18-65 years of age who have chronic SCI ≥ 1 year prior will be recruited. Physical activity measures will be taken using wrist-based accelerometers and the Leisure Time Physical Activity Questionnaire for people with SCI (LTPAQ). Psychosocial factors will be evaluated through questionnaires. The primary health outcome measure (aPWV), and secondary cardiovascular parameters will be assessed using a combination of echocardiography and ultrasound. Fitness will be determined using a peak oxygen consumption test on an arm-cycle ergometer. All measurement will be taken at baseline and after 9 weeks following intervention commencement. Physical activity will also be sampled mid-intervention at 4 and 7 weeks. Training will involve weekly, 10-15 minute coaching sessions for 9 weeks. All pre- and post-assessments will take place at the Blusson Spinal Cord Centre at ICORD. Intervention content will be delivered in-person, over Skype or phone, and the wrist- worn accelerometers will be delivered and picked up from the participant's home during the intervention.
Detailed description
A randomized, wait-list controlled trial will be used to compare the effects of tailored PA coaching sessions versus no coaching on PA behaviour, psychosocial factors, and health outcomes. Eligible individuals will be randomly assigned (1:1) to either the experimental (PA coaching sessions) or wait-list control condition. Matched randomization based on baseline physical activity levels will be used. The randomization sequence will be generated by a research assistant independent of the trial. Day 1 testing measures include vascular measures (arterial pulse wave velocity, arterial structure; 30 minutes), cardiac structure and function measures (30 minutes), a peak oxygen uptake test (60 minutes), for a total duration of 2 hours. Participants will be given an accelerometer to wear for the 6-day monitoring period (6.1.2) after which they will return for Day 2 testing. Day 2 testing measures include administration of the LTPAQ (5 minutes), administration of the demographics and Health Action Process Approach model questionnaire (25 minutes), and a measurement of energy expenditure at different sub-maximal wheeling speeds to calibrate MVPA cut-points (30 minutes) and at baseline, the first PA coaching session will be administered (60 minutes) whereas at post-test a semi-structured interview will be administered (60 minutes). Total duration of day 2 testing will be 2 hours. The intervention protocol is described below. During the intervention, physical activity will be sampled at two time points; accelerometer and PARA SCI data will be taken during week 4 and week 7. INTERVENTION Intervention Protocol: Experimental participants will receive weekly PA coaching sessions. Each session will be 10-15 minutes in duration and delivered either face to face, over Skype, or when the former modes are unavailable, over the phone. Additionally, supplemental resources may be emailed to the participants based on need throughout the intervention. Participants' motivation to exercise will first be determined according to stages of the HAPA model. Those who identify as pre-intenders (no intention to exercise) will receive intervention strategies that focus on changing motivation to be physically active. Those identified as intenders (willing to exercise but have not started) will focus on providing resources and behavioural strategies to commence physical activity. Lastly, those identified as actors (already exercising) will receive intervention strategies that help participants maintain or improve PA behaviour. For those in the intender or actor stage, the intervention aims to promote the international SCI PA guidelines to promote fitness (at least 20 minutes of moderate vigorous aerobic activity twice/week and strength training twice/week). For those exceeding the fitness guidelines, the international SCI PA guidelines to promote health are promoted (at least 30 minutes of moderate to vigorous aerobic activity three times/week and strength training twice/week). However, these aims will be modified based on the individual's baseline PA. During the first visit, participants' baseline PA levels will be reviewed and an appropriate PA goal to achieve in the following month will be formed. Ultimately, the goal is the decision of the participant. Following goal setting, barriers to participating in PA will be identified. The interventionist will select intervention strategies based on the identified barriers. A pre-formed chart of corresponding intervention strategies (e.g. use of behaviour change techniques, referral to facilities or peers, suggesting at-home exercises) was developed to aid this pairing process (Appendix A). These intervention strategies are accompanied by a comprehensive toolkit based from the HAPA model (Appendix B). In brief, the toolkit advises on three key strategies for promoting PA to people with SCI: i) education, ii) referral, iii) tailored PA prescription. Remaining weekly coaching sessions will review participants' progress and barriers to discuss new goals and strategies as outlined above. Control Participants: Control participants will complete baseline and post-testing only. Following completion of post-test measures they will be administered the same PA coaching session as the intervention group, with post-test measures being repeated upon intervention completion.
Interventions
Participants will receive weekly physical activity coaching sessions. Each session will be 10-15 minutes, delivered either face to face, over Skype, or over the phone. Additional resources may be emailed to participants based on need throughout the intervention (for example, a goal, list of places to exercise, contact information to reach mentoring services). A typical session may include: 1. An assessment of motivated the participant is to be physically active 2. A: If motivated, a physical activity goal will be set, strategies will be reviewed, and resources to accomplish that goal will be provided. B: If not motivated, questions will be asked to understand why the reasons for lack of motivation. If it is for any reasons including barriers, fear, confidence, or knowledge, the interventionist will discuss strategies to overcome these obstacles. 3. Progress and barriers will be reassessed and discussed.
Sponsors
Study design
Eligibility
Inclusion criteria
* Individuals must be competent to give informed consent, * be able to propel an arm ergometer.
Exclusion criteria
* History and/or symptoms of CVD or cardiopulmonary problems/disease. * Major trauma or surgery within the last 6 months. * Active Stage 3 or 4 pressure ulcer (based on the National Pressure Ulcer Advisory Panel classification) * Recent (within 1 year) history of lower-extremity or non-union fracture * Any unstable medical/psychiatric condition or substance abuse disorder that is likely to affect their ability to complete this study. * Individuals with active medical issues such as pressure sores, urinary tract infections, hypertension, or heart disorders. * Any cognitive dysfunction or language barrier that would prevent subjects from following English instructions. * Subjects may be excluded at the discretion of the principal investigator due to other, unforeseen, safety issues.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ) | Baseline, week 4, week 7, week 10, 6 month follow up | Participants will be asked to complete a questionnaire, guided by the co-investigator (Jasmin Ma), that asks the participant to recall in the last 7 days how many days and for how long leisure time physical activity was performed. The recall assessment will take approximately 5 minutes to complete. |
| Change in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring Period | Baseline, week 4, week 7, week 10 | Participants will be fitted with a wrist-based tri-axial accelerometer to be worn 24 hours a day for 6 days in order to determine intensity and amount of PA. They will keep a detailed PA diary recording all leisure time PA performed during the day. The primary outcome will be total vector magnitude (VM) accelerometer counts from a tri-axial wrist-worn accelerometer (GT9X, ActiGraph LLC, FL). During the intervention, the accelerometer will be picked up and dropped off to the participant's home to decrease burden. Text or email reminders (i.e. Please don't forget to wear your accelerometer today) will be used to promote adherence to accelerometer wear. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Pulse Wave Velocity | Baseline, 9 weeks from intervention start (week 10) | aPWV (cm/s) is calculated by dividing the distance between measurement sites, by the pulse transit time. Distance between the carotid and femoral arteries will be measured using measuring tape along the surface of the body, held parallel to the testing table. The pulse transit is determined from the arterial blood pressure waves, which are collected at each arterial site. A pen-like device (model SPT-301; Millar Instruments Inc., Houston, TX) will be applied to the carotid and femoral arterial sites using a light pressure to obtain arterial pressure waves. Heart rate will be recorded using a single-lead (lead I) electrocardiogram (ECG) (model ML 123, ADInstruments Inc., Colorado Springs, CO). |
| Change in Arterial Structure: Wall Thickness | Baseline, 9 weeks from intervention start (week 10) | Common carotid arterial images will be collected using B-mode ultrasound (INFO) for 10 cardiac cycles. Images will be analyzed using internal ultrasound software to determine lumen diameter and intima-media thickness. |
| Change in End Systolic Volume | Baseline, 9 weeks from intervention start (week 10) | Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis. |
| Change in End Diastolic Volume | Baseline, 9 weeks from intervention start (week 10) | Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis. |
| Change in Intraventricular Septum Diameter | Baseline, 9 weeks from intervention start (week 10) | Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis. |
| Change in Ventricular Internal Diameter | Baseline, 9 weeks from intervention start (week 10) | Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis. |
| Change in Health Action Process Approach Model Measure | Baseline, 9 weeks from intervention start (week 10) | This survey will examine psychological factors that may affect PA participation. The survey will be recorded either electronically or with pen and paper depending on the respondent's preference. Survey will take approximately 25 minutes to complete, and will assess constructs related to exercise such as perceived risks, self- efficacy, planning, and social support. The demographics questionnaire will also be administered with this measure. All items will be assessed on a 7-point Likert scale ranging from 1 = strongly disagree to 7 = strongly agree. Higher scores indicate a better outcome. |
| Change in Ejection Fraction | Baseline, 9 weeks from intervention start (week 10) | Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis. |
| Change in Cardiac Output | Baseline, 9 weeks from intervention start (week 10) | Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis. |
| Change in Fractional Shortening | Baseline, 9 weeks from intervention start (week 10) | Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis. Longitudinal strain will be used to measure change in fractional shortening. |
| Change in Diastolic Function | Baseline, 9 weeks from intervention start (week 10) | Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis. E'/A' (ratio between early diastolic septal tissue velocity and late diastolic septal tissue velocity) will be used to measure change in diastolic function. |
| Aerobic Fitness Evaluation: Peak Oxygen Uptake Test (VO2peak) | Baseline, 9 weeks from intervention start (week 10) | Participants will perform a graded arm ergometer test on an electronically braked arm ergometer. For participants with tetraplegia who have limited handgrip function, gloves will be used to secure hands to the ergometer handles. Participants will be instructed to maintain a cycling rate of 50 revolutions per minute (rpm) for the duration of the test. After an initial warm-up at 0W, power output will be increased each minute at a rate of 2-5 W/min for participants with tetraplegia, or 10 W/min for participants with paraplegia, until volitional exhaustion (i.e. dropping below 30 rpm). Oxygen consumption will be recorded on a breath-by-breath basis for the duration of the test and reported as rolling 30-second averages sampled at 5-second intervals as per consensus recommendations. All outcome data are reported here: https://doi.org/10.1007/s40279-019-01118-5 |
| Change in Systolic Function | Baseline, 9 weeks from intervention start (week 10) | Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis. LV stroke volume will be used to measure change in systolic function. |
| Number of Participants Participating in Qualitative Interviews | 9 weeks from intervention start (week 10) | A semi-structured interview will be conducted at the end of the intervention to understand what components were and were not effective. Data will not be recorded. This feedback will be used to improve future iterations of the intervention. There is no associated scale with this measurement. |
Countries
Canada
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| ProacTive SCI Individualized physical activity coaching sessions
ProacTive SCI: Participants will receive weekly physical activity coaching sessions. Each session will be 10-15 minutes, delivered either face to face, over Skype, or over the phone. Additional resources may be emailed to participants based on need throughout the intervention (for example, a goal, list of places to exercise, contact information to reach mentoring services). A typical session may include:
1. An assessment of motivated the participant is to be physically active
2. A: If motivated, a physical activity goal will be set, strategies will be reviewed, and resources to accomplish that goal will be provided.
B: If not motivated, questions will be asked to understand why the reasons for lack of motivation. If it is for any reasons including barriers, fear, confidence, or knowledge, the interventionist will discuss strategies to overcome these obstacles.
3. Progress and barriers will be reassessed and discussed. | 14 |
| Wait-list Control Standard care, receiving physical activity coaching sessions after completing post-testing | 14 |
| Total | 28 |
Baseline characteristics
| Characteristic | Total | Wait-list Control | ProacTive SCI |
|---|---|---|---|
| Aerobic Fitness Evaluation: Peak Oxygen Uptake Test (VO2peak) | 1.14 L/min STANDARD_DEVIATION 0.41 | 1.13 L/min STANDARD_DEVIATION 0.43 | 1.15 L/min STANDARD_DEVIATION 0.36 |
| Age, Continuous | 45.68 years STANDARD_DEVIATION 11.93 | 45.57 years STANDARD_DEVIATION 10.49 | 45.79 years STANDARD_DEVIATION 13.63 |
| Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ) | 243 Total LTPA min/week STANDARD_DEVIATION 248 | 274 Total LTPA min/week STANDARD_DEVIATION 300 | 212 Total LTPA min/week STANDARD_DEVIATION 195 |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 4 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 22 Participants | 10 Participants | 12 Participants |
| Region of Enrollment Canada | 28 participants | 14 participants | 14 participants |
| Sex: Female, Male Female | 13 Participants | 8 Participants | 5 Participants |
| Sex: Female, Male Male | 15 Participants | 6 Participants | 9 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 14 | 0 / 14 |
| other Total, other adverse events | 0 / 14 | 0 / 14 |
| serious Total, serious adverse events | 0 / 14 | 0 / 14 |
Outcome results
Change in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ)
Participants will be asked to complete a questionnaire, guided by the co-investigator (Jasmin Ma), that asks the participant to recall in the last 7 days how many days and for how long leisure time physical activity was performed. The recall assessment will take approximately 5 minutes to complete.
Time frame: Baseline, week 4, week 7, week 10, 6 month follow up
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ProacTive SCI | Change in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ) | Week 7 | 370 Total LTPA min/week | Standard Deviation 258 |
| ProacTive SCI | Change in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ) | Baseline | 212 Total LTPA min/week | Standard Deviation 195 |
| ProacTive SCI | Change in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ) | Week 4 | 393 Total LTPA min/week | Standard Deviation 413 |
| ProacTive SCI | Change in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ) | 6 months FU | 348 Total LTPA min/week | Standard Deviation 269 |
| ProacTive SCI | Change in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ) | Week 10 | 405 Total LTPA min/week | Standard Deviation 364 |
| Wait-list Control | Change in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ) | 6 months FU | NA Total LTPA min/week | — |
| Wait-list Control | Change in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ) | Week 4 | NA Total LTPA min/week | — |
| Wait-list Control | Change in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ) | Week 7 | NA Total LTPA min/week | — |
| Wait-list Control | Change in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ) | Week 10 | 147 Total LTPA min/week | Standard Deviation 192 |
| Wait-list Control | Change in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ) | Baseline | 274 Total LTPA min/week | Standard Deviation 300 |
Change in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring Period
Participants will be fitted with a wrist-based tri-axial accelerometer to be worn 24 hours a day for 6 days in order to determine intensity and amount of PA. They will keep a detailed PA diary recording all leisure time PA performed during the day. The primary outcome will be total vector magnitude (VM) accelerometer counts from a tri-axial wrist-worn accelerometer (GT9X, ActiGraph LLC, FL). During the intervention, the accelerometer will be picked up and dropped off to the participant's home to decrease burden. Text or email reminders (i.e. Please don't forget to wear your accelerometer today) will be used to promote adherence to accelerometer wear.
Time frame: Baseline, week 4, week 7, week 10
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ProacTive SCI | Change in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring Period | Week 7 | 659000 Accelerometer total VM counts | Standard Deviation 338000 |
| ProacTive SCI | Change in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring Period | Baseline | 562000 Accelerometer total VM counts | Standard Deviation 188000 |
| ProacTive SCI | Change in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring Period | Week 10 | 702000 Accelerometer total VM counts | Standard Deviation 267000 |
| ProacTive SCI | Change in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring Period | Week 4 | 593000 Accelerometer total VM counts | Standard Deviation 307000 |
| Wait-list Control | Change in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring Period | Week 10 | 598000 Accelerometer total VM counts | Standard Deviation 390000 |
| Wait-list Control | Change in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring Period | Week 7 | NA Accelerometer total VM counts | — |
| Wait-list Control | Change in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring Period | Week 4 | NA Accelerometer total VM counts | — |
| Wait-list Control | Change in Total Accelerometer Count as a Measure of Change in Physical Activity: 6-day Physical Activity Monitoring Period | Baseline | 848000 Accelerometer total VM counts | Standard Deviation 759000 |
Aerobic Fitness Evaluation: Peak Oxygen Uptake Test (VO2peak)
Participants will perform a graded arm ergometer test on an electronically braked arm ergometer. For participants with tetraplegia who have limited handgrip function, gloves will be used to secure hands to the ergometer handles. Participants will be instructed to maintain a cycling rate of 50 revolutions per minute (rpm) for the duration of the test. After an initial warm-up at 0W, power output will be increased each minute at a rate of 2-5 W/min for participants with tetraplegia, or 10 W/min for participants with paraplegia, until volitional exhaustion (i.e. dropping below 30 rpm). Oxygen consumption will be recorded on a breath-by-breath basis for the duration of the test and reported as rolling 30-second averages sampled at 5-second intervals as per consensus recommendations. All outcome data are reported here: https://doi.org/10.1007/s40279-019-01118-5
Time frame: Baseline, 9 weeks from intervention start (week 10)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ProacTive SCI | Aerobic Fitness Evaluation: Peak Oxygen Uptake Test (VO2peak) | Baseline | 1.16 L/min | Standard Deviation 0.38 |
| ProacTive SCI | Aerobic Fitness Evaluation: Peak Oxygen Uptake Test (VO2peak) | Week 10 | 1.30 L/min | Standard Deviation 0.43 |
| Wait-list Control | Aerobic Fitness Evaluation: Peak Oxygen Uptake Test (VO2peak) | Baseline | 1.13 L/min | Standard Deviation 0.46 |
| Wait-list Control | Aerobic Fitness Evaluation: Peak Oxygen Uptake Test (VO2peak) | Week 10 | 1.06 L/min | Standard Deviation 0.4 |
Change in Arterial Structure: Wall Thickness
Common carotid arterial images will be collected using B-mode ultrasound (INFO) for 10 cardiac cycles. Images will be analyzed using internal ultrasound software to determine lumen diameter and intima-media thickness.
Time frame: Baseline, 9 weeks from intervention start (week 10)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ProacTive SCI | Change in Arterial Structure: Wall Thickness | Baseline | 0.62 mm | Standard Deviation 0.16 |
| ProacTive SCI | Change in Arterial Structure: Wall Thickness | Week 10 | 0.61 mm | Standard Deviation 0.15 |
| Wait-list Control | Change in Arterial Structure: Wall Thickness | Baseline | 0.56 mm | Standard Deviation 0.07 |
| Wait-list Control | Change in Arterial Structure: Wall Thickness | Week 10 | 0.56 mm | Standard Deviation 0.07 |
Change in Cardiac Output
Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis.
Time frame: Baseline, 9 weeks from intervention start (week 10)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ProacTive SCI | Change in Cardiac Output | Baseline | 3.22 L/min | Standard Deviation 0.78 |
| ProacTive SCI | Change in Cardiac Output | Week 10 | 3.13 L/min | Standard Deviation 0.63 |
| Wait-list Control | Change in Cardiac Output | Baseline | 3.05 L/min | Standard Deviation 0.87 |
| Wait-list Control | Change in Cardiac Output | Week 10 | 3.13 L/min | Standard Deviation 0.96 |
Change in Diastolic Function
Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis. E'/A' (ratio between early diastolic septal tissue velocity and late diastolic septal tissue velocity) will be used to measure change in diastolic function.
Time frame: Baseline, 9 weeks from intervention start (week 10)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ProacTive SCI | Change in Diastolic Function | Baseline | 0.99 Ratio | Standard Deviation 0.21 |
| ProacTive SCI | Change in Diastolic Function | Week 10 | 1.02 Ratio | Standard Deviation 0.32 |
| Wait-list Control | Change in Diastolic Function | Baseline | 1.10 Ratio | Standard Deviation 0.33 |
| Wait-list Control | Change in Diastolic Function | Week 10 | 1.14 Ratio | Standard Deviation 0.36 |
Change in Ejection Fraction
Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis.
Time frame: Baseline, 9 weeks from intervention start (week 10)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ProacTive SCI | Change in Ejection Fraction | Baseline | 57 % of blood ejected per contraction | Standard Deviation 3 |
| ProacTive SCI | Change in Ejection Fraction | Week 10 | 56 % of blood ejected per contraction | Standard Deviation 3 |
| Wait-list Control | Change in Ejection Fraction | Baseline | 57 % of blood ejected per contraction | Standard Deviation 3 |
| Wait-list Control | Change in Ejection Fraction | Week 10 | 58 % of blood ejected per contraction | Standard Deviation 3 |
Change in End Diastolic Volume
Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis.
Time frame: Baseline, 9 weeks from intervention start (week 10)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ProacTive SCI | Change in End Diastolic Volume | Baseline | 87 ml | Standard Deviation 18 |
| ProacTive SCI | Change in End Diastolic Volume | Week 10 | 86 ml | Standard Deviation 14 |
| Wait-list Control | Change in End Diastolic Volume | Baseline | 84 ml | Standard Deviation 20 |
| Wait-list Control | Change in End Diastolic Volume | Week 10 | 82 ml | Standard Deviation 18 |
Change in End Systolic Volume
Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis.
Time frame: Baseline, 9 weeks from intervention start (week 10)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ProacTive SCI | Change in End Systolic Volume | Baseline | 38 ml | Standard Deviation 9 |
| ProacTive SCI | Change in End Systolic Volume | Week 10 | 38 ml | Standard Deviation 9 |
| Wait-list Control | Change in End Systolic Volume | Baseline | 36 ml | Standard Deviation 9 |
| Wait-list Control | Change in End Systolic Volume | Week 10 | 35 ml | Standard Deviation 8 |
Change in Fractional Shortening
Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis. Longitudinal strain will be used to measure change in fractional shortening.
Time frame: Baseline, 9 weeks from intervention start (week 10)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ProacTive SCI | Change in Fractional Shortening | Baseline | -19.0 % change from original length | Standard Deviation 2.6 |
| ProacTive SCI | Change in Fractional Shortening | Week 10 | -19.2 % change from original length | Standard Deviation 2.7 |
| Wait-list Control | Change in Fractional Shortening | Baseline | -17.5 % change from original length | Standard Deviation 4.3 |
| Wait-list Control | Change in Fractional Shortening | Week 10 | -18.1 % change from original length | Standard Deviation 3.3 |
Change in Health Action Process Approach Model Measure
This survey will examine psychological factors that may affect PA participation. The survey will be recorded either electronically or with pen and paper depending on the respondent's preference. Survey will take approximately 25 minutes to complete, and will assess constructs related to exercise such as perceived risks, self- efficacy, planning, and social support. The demographics questionnaire will also be administered with this measure. All items will be assessed on a 7-point Likert scale ranging from 1 = strongly disagree to 7 = strongly agree. Higher scores indicate a better outcome.
Time frame: Baseline, 9 weeks from intervention start (week 10)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Barrier self-efficacy (Baseline) | 5.0 score on a scale | Standard Deviation 1.2 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Aerobic exercise task self-efficacy (Week 10) | 4.7 score on a scale | Standard Deviation 1.2 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Strength exercise task self-efficacy (Baseline) | 3.9 score on a scale | Standard Deviation 1.6 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Aerobic exercise task self-efficacy (Baseline) | 3.4 score on a scale | Standard Deviation 1.9 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Strength exercise task self-efficacy (Week 10) | 5.6 score on a scale | Standard Deviation 1.2 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Barrier self-efficacy (Week 10) | 5.7 score on a scale | Standard Deviation 0.8 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Scheduling self-efficacy (Baseline) | 4.9 score on a scale | Standard Deviation 1.5 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Instrumental outcome expectancies (Baseline) | 6.5 score on a scale | Standard Deviation 0.6 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Planning self-efficacy (Week 10) | 6.0 score on a scale | Standard Deviation 0.5 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Action planning (Baseline) | 3.7 score on a scale | Standard Deviation 1.9 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Monitoring (Baseline) | 4.5 score on a scale | Standard Deviation 1.6 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Scheduling self-efficacy (Week 10) | 5.7 score on a scale | Standard Deviation 1.3 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Affective outcome expectancies (Week 10) | 5.6 score on a scale | Standard Deviation 1 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Action planning (Week 10) | 6.8 score on a scale | Standard Deviation 0.4 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Intentions (Baseline) | 6.1 score on a scale | Standard Deviation 1.1 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Risk perceptions (Baseline) | 2.5 score on a scale | Standard Deviation 1.6 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Monitoring (Week 10) | 6.3 score on a scale | Standard Deviation 0.8 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Coping self-efficacy (Baseline) | 6.0 score on a scale | Standard Deviation 0.8 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Intentions (Week 10) | 6.8 score on a scale | Standard Deviation 0.4 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Coping self-efficacy (Week 10) | 6.3 score on a scale | Standard Deviation 0.7 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Social support (Baseline) | 2.2 score on a scale | Standard Deviation 1 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Affective outcome expectancies (Baseline) | 5.1 score on a scale | Standard Deviation 1.3 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Social support (Week 10) | 2.8 score on a scale | Standard Deviation 0.9 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Planning self-efficacy (Baseline) | 5.9 score on a scale | Standard Deviation 0.8 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Presence of barriers (Baseline) | 5.7 score on a scale | Standard Deviation 1.5 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Presence of barriers (Week 10) | 6.1 score on a scale | Standard Deviation 1.1 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Knowledge (Baseline) | 5.9 score on a scale | Standard Deviation 1.1 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Risk perceptions (Week 10) | 2.8 score on a scale | Standard Deviation 1.6 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Knowledge (Week 10) | 6.7 score on a scale | Standard Deviation 0.4 |
| ProacTive SCI | Change in Health Action Process Approach Model Measure | Instrumental outcome expectancies (Week 10) | 6.8 score on a scale | Standard Deviation 0.3 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Knowledge (Week 10) | 4.4 score on a scale | Standard Deviation 2 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Affective outcome expectancies (Week 10) | 5.4 score on a scale | Standard Deviation 1 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Instrumental outcome expectancies (Week 10) | 6.3 score on a scale | Standard Deviation 0.8 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Aerobic exercise task self-efficacy (Baseline) | 4.1 score on a scale | Standard Deviation 1.7 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Aerobic exercise task self-efficacy (Week 10) | 3.6 score on a scale | Standard Deviation 1.6 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Intentions (Baseline) | 6.5 score on a scale | Standard Deviation 0.7 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Planning self-efficacy (Week 10) | 6.8 score on a scale | Standard Deviation 0.4 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Barrier self-efficacy (Baseline) | 4.4 score on a scale | Standard Deviation 1 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Scheduling self-efficacy (Week 10) | 5.5 score on a scale | Standard Deviation 1.1 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Monitoring (Week 10) | 4.4 score on a scale | Standard Deviation 1.3 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Coping self-efficacy (Week 10) | 6.3 score on a scale | Standard Deviation 0.7 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Presence of barriers (Baseline) | 5.5 score on a scale | Standard Deviation 1.3 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Presence of barriers (Week 10) | 5.0 score on a scale | Standard Deviation 1.8 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Affective outcome expectancies (Baseline) | 5.7 score on a scale | Standard Deviation 0.9 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Instrumental outcome expectancies (Baseline) | 6.5 score on a scale | Standard Deviation 0.9 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Risk perceptions (Week 10) | 2.5 score on a scale | Standard Deviation 1.1 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Strength exercise task self-efficacy (Baseline) | 3.7 score on a scale | Standard Deviation 1.6 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Strength exercise task self-efficacy (Week 10) | 3.2 score on a scale | Standard Deviation 1.8 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Intentions (Week 10) | 6.3 score on a scale | Standard Deviation 1.2 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Planning self-efficacy (Baseline) | 6.2 score on a scale | Standard Deviation 1.1 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Barrier self-efficacy (Week 10) | 4.7 score on a scale | Standard Deviation 1.1 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Scheduling self-efficacy (Baseline) | 5.3 score on a scale | Standard Deviation 1.2 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Action planning (Baseline) | 3.8 score on a scale | Standard Deviation 2 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Action planning (Week 10) | 3.6 score on a scale | Standard Deviation 2.3 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Monitoring (Baseline) | 4.4 score on a scale | Standard Deviation 1.4 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Coping self-efficacy (Baseline) | 5.8 score on a scale | Standard Deviation 1.2 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Social support (Baseline) | 2.0 score on a scale | Standard Deviation 0.8 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Social support (Week 10) | 1.7 score on a scale | Standard Deviation 0.5 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Knowledge (Baseline) | 5.2 score on a scale | Standard Deviation 1.9 |
| Wait-list Control | Change in Health Action Process Approach Model Measure | Risk perceptions (Baseline) | 2.5 score on a scale | Standard Deviation 1.3 |
Change in Intraventricular Septum Diameter
Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis.
Time frame: Baseline, 9 weeks from intervention start (week 10)
Population: This was not measured or reported.
Change in Pulse Wave Velocity
aPWV (cm/s) is calculated by dividing the distance between measurement sites, by the pulse transit time. Distance between the carotid and femoral arteries will be measured using measuring tape along the surface of the body, held parallel to the testing table. The pulse transit is determined from the arterial blood pressure waves, which are collected at each arterial site. A pen-like device (model SPT-301; Millar Instruments Inc., Houston, TX) will be applied to the carotid and femoral arterial sites using a light pressure to obtain arterial pressure waves. Heart rate will be recorded using a single-lead (lead I) electrocardiogram (ECG) (model ML 123, ADInstruments Inc., Colorado Springs, CO).
Time frame: Baseline, 9 weeks from intervention start (week 10)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ProacTive SCI | Change in Pulse Wave Velocity | Baseline | 10.6 cm/s | Standard Deviation 2.9 |
| ProacTive SCI | Change in Pulse Wave Velocity | Week 10 | 9.7 cm/s | Standard Deviation 2.5 |
| Wait-list Control | Change in Pulse Wave Velocity | Baseline | 8.0 cm/s | Standard Deviation 2 |
| Wait-list Control | Change in Pulse Wave Velocity | Week 10 | 8.2 cm/s | Standard Deviation 1.9 |
Change in Systolic Function
Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis. LV stroke volume will be used to measure change in systolic function.
Time frame: Baseline, 9 weeks from intervention start (week 10)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ProacTive SCI | Change in Systolic Function | Baseline | 49 ml | Standard Deviation 9 |
| ProacTive SCI | Change in Systolic Function | Week 10 | 49 ml | Standard Deviation 6 |
| Wait-list Control | Change in Systolic Function | Baseline | 48 ml | Standard Deviation 11 |
| Wait-list Control | Change in Systolic Function | Week 10 | 47 ml | Standard Deviation 10 |
Change in Ventricular Internal Diameter
Cardiac image will be collected non-invasively using Doppler ultrasound (Vivid q, GE Healthcare, Buckinghamshire, UK). Image will be collected and stored on the ultrasound for offline analysis.
Time frame: Baseline, 9 weeks from intervention start (week 10)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ProacTive SCI | Change in Ventricular Internal Diameter | Baseline | 42 mm | Standard Deviation 5 |
| ProacTive SCI | Change in Ventricular Internal Diameter | Week 10 | 43 mm | Standard Deviation 4 |
| Wait-list Control | Change in Ventricular Internal Diameter | Baseline | 43 mm | Standard Deviation 10 |
| Wait-list Control | Change in Ventricular Internal Diameter | Week 10 | 44 mm | Standard Deviation 4 |
Number of Participants Participating in Qualitative Interviews
A semi-structured interview will be conducted at the end of the intervention to understand what components were and were not effective. Data will not be recorded. This feedback will be used to improve future iterations of the intervention. There is no associated scale with this measurement.
Time frame: 9 weeks from intervention start (week 10)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| ProacTive SCI | Number of Participants Participating in Qualitative Interviews | 14 Participants |
| Wait-list Control | Number of Participants Participating in Qualitative Interviews | 0 Participants |